Researchers at Tampere University, Finland, have developed a groundbreaking 3D-printed ceramic implant material that closely mimics real human bone.
With FDA clearance in hand, Rivanna highlighted that it will accelerate the development of further AI capabilities for the Accuro XV system.
FORT LAUDERDALE, Fla., May 7, 2026 /PRNewswire/ — Spinal Resources, Inc., a developer of advanced spinal stabilization technologies, today announced the issuance of U.S. Patent No. 12,611,231, “Spinal Rod and Systems Thereof”.
ADDISON, Texas, May 5, 2026 /PRNewswire/ — FX Shoulder Solutions, Inc. has received FDA 510(k) clearance for the FX V135® Easytech Shoulder System, the next generation of stemless shoulder arthroplasty implants that provides surgeons with an anatomic stemless versus a modular stemmed-reverse option. This design enables surgeons to begin with a stemless approach and, when clinically appropriate, transition intraoperatively to a short stem solution without changing or adding another system.
GRAND RAPIDS, Mich., April 30, 2026 /PRNewswire/ — Capitan Orthopedics, Inc. (https://capitanortho.com/) announced today that it has been granted Breakthrough Device Designation from the U.S. Food & Drug Administration (FDA) for its SupraSpacerTM implant.
FDA authorization marks critical milestone enabling advancement of next-generation bone regeneration therapy for patients with degenerative spinal diseases
HERSHEY, Pa., April 29, 2026 /PRNewswire/ — Chest Wall Innovations, a medical device company focused on advancing the standard of care in chest wall surgery, today announced that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for its PC Fix Rib Fixation System on April 24, 2026, clearing the path for U.S. commercialization.
The King’s College London team tested the wool-based keratin in animal models and found the material was able to guide new bone growth across damaged areas.
LEXINGTON, Mass., April 21, 2026 (GLOBE NEWSWIRE) — Hyalex Orthopaedics today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its HYALEX Slalom™ MTP Hemiarthroplasty Implant, a next-generation implant designed around the proprietary Hydrosurf™ materials platform, for the treatment of degenerative conditions affecting the first metatarsophalangeal (MTP) joint, including hallux rigidus.
The CYBORG study aims to assess the efficacy, safety and usability of the system.